The FDA delays final rule related to off-label use; Amgen’s Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca’s hyperkalaemia drug
Five things for pharma marketers to know: Tuesday, March 14, 2017
Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project
Five things for pharma marketers to know: Tuesday, February 21, 2017
Pharma industry remains focused on Alzheimer’s, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena
Roche gears up to enter loaded hemophilia A drug market
A loaded hemophilia A drug market is an indication patients in and around it are well-served, but that hasn’t stopped contenders such as Roche’s emicizumab.
Five things for pharma marketers to know: Wednesday, February 15, 2017
Pharma execs raise concerns about Trump’s plans for the FDA; Merck ends study of experimental Alzheimer’s drug; Amgen seeks new indication for Blincyto
Five things for pharma marketers to know: Tuesday, February 7, 2017